Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7336 to 7350 of 7708 results

  1. Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA1007.

  2. Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour (IPG744)

    June 2023: We are aware that the International Journal of Gynecology and Obstetrics has retracted a 2016 paper, which was used in committee decision making for this topic (IPG744). As the evidence base has now changed, it is returning to committee for re-discussion, see NICE's in-development webpage on balloon disimpaction of the baby’s head at emergency caesarean during the second stage of labour. Once the schedule for this has been confirmed, it will be communicated to stakeholders and published on the NICE website. In the meantime, please read the NIHR updated process to oversee the safe introduction of new procedures (PDF only).

  3. Surgical correction of hallux valgus using minimal access techniques (IPG332)

    This guidance has been updated and replaced by NICE interventional procedures guidance 789

  4. Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]

    In development [GID-TA11166] Expected publication date: TBC

  5. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    In development [GID-TA11089] Expected publication date: TBC

  6. Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007

    In development [GID-TA11567] Expected publication date: TBC

  7. Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920

    In development [GID-TA11482] Expected publication date: TBC

  8. Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

    In development [GID-TA10745] Expected publication date: 17 July 2024

  9. Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

    This guidance has been updated and replaced by NICE technology appraisal guidance 988.

  10. Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461]

    In development [GID-TA11580] Expected publication date: TBC

  11. Common mental health problems: identification and pathways to care (CG123)

    We withdrew this guideline in May 2024, because all of the recommendations are now covered in other NICE guidelines, or are out of date and no longer relevant to clinical practice. For guidance on common mental health problems, see our guidelines on:

  12. Intrapartum care for healthy women and babies - rectal examination after delivery

    Discontinued [GID-NG10395]

  13. Violence and aggression: short-term management in mental health, health and community settings

    Discontinued [GID-NG10397]

  14. Peezy Midstream for urine collection (MT446)

    In development [GID-MT538] Expected publication date: TBC